LLY (Eli Lilly and Company) has a reliability-weighted signal score of 59/100 on StockMarketSignals, based on 1 finance YouTuber over a rolling 14-day window. The score reflects how strongly tracked creators are currently bullish or bearish on LLY, weighted by each channel's reliability.
Why analysts are watching it
Analysts are watching Eli Lilly (LLY) following strong performance from its diabetes and obesity drug, Mounjaro. On May 24, 2026, Couch Investor noted in his video "I'm Thinking About Buying Next Week. Here's My Full Plan" that Mounjaro achieved bestselling drug status in Q1 2026, generating $8.7 billion in revenue. This significant sales figure suggests continued growth potential for the company. However, competition in the pharmaceutical sector remains a key risk.
Contributing creators
Source clips
"Then we have here Eli Liy and Merk's cancer drug. Here you can see that last quarter in Q1 2026, Monurro from Eli Liy became the bestselling drug, $8.7 billion."
— I'm Thinking About Buying Next Week. Here's My Full Plan